Moazzam Shehanshah Wali, Mobeen Abdul, Siddiqui Mansoor Ahmad
Dept. of Moalajat, Hakeem Rais Unani Medical College and Hospital, Sambhal, Uttar Pardesh, India.
Dept. of Moalajat, National Institute of Unani Medicine, Bangalore, 560091, India.
J Tradit Complement Med. 2022 Apr 22;12(6):529-535. doi: 10.1016/j.jtcme.2022.04.004. eCollection 2022 Nov.
Irritable bowel syndrome (IBS) is one of the most common gastrointestinal disorders characterized by chronic recurrent abdominal pain related to a change in bowel habit or defecation frequency and commonly accompanied by anxiety and depression affecting about 10% population globally. Jawarish Shahi (JS) is a special dosage form prepared for gastrointestinal disorders in Unani medicine containing L., Retz., L., (L.) Maton and L. Considering the antioxidant, immunomodulatory, antispasmodic analgesic, antidiarrheal, antisecretory, laxative, anti-inflammatory, anxiolytic, and antidepressant properties, the present study was aimed to evaluate the efficacy of JS in IBS.
This single-arm open-labeled clinical trial was conducted on 26 male and female patients of IBS according to Rome IV criteria, aged 18-50 years with moderate symptoms. JS was given 7 g orally twice a day after meal with water for 45 days. IBS Severity Scoring Scale (IBS-SSS) was used for efficacy outcomes and the difference was analyzed from baseline to the subsequent follow-ups.
Data analysis of subsequent followup showed a significant decrease in IBS-SSS scores except for 2nd followup, scores decreased from 229.50 ± 75.91 to 203.12 ± 71.71 (p < 0.1018), 150.61 ± 55.32 (p < 0.0001), and 123.76 ± 54.81 (p < 0.0001) at 0, 15th, 30th, 45th day of follow up respectively.
The present study revealed that JS is safe and effective in reducing the overall symptoms of IBS in respect to its severity and impact on quality of life and can be used as an alternate as well as a complementary treatment in IBS.
肠易激综合征（IBS）是最常见的胃肠道疾病之一，其特征为与排便习惯或排便频率改变相关的慢性复发性腹痛，常伴有焦虑和抑郁，全球约10%的人口受其影响。Jawarish Shahi（JS）是一种为尤纳尼医学中胃肠道疾病制备的特殊剂型，含有[具体植物名称未完整给出]。鉴于其抗氧化、免疫调节、解痉镇痛、止泻、抗分泌、通便、抗炎、抗焦虑和抗抑郁特性，本研究旨在评估JS对IBS的疗效。
本单臂开放标签临床试验根据罗马IV标准，对26例年龄在18 - 50岁、症状中度的IBS男性和女性患者进行。JS以7克剂量，每日两次，饭后用水口服，持续45天。使用肠易激综合征严重程度评分量表（IBS - SSS）评估疗效，并分析从基线到后续随访的差异。
后续随访的数据分析显示，除第二次随访外，IBS - SSS评分显著降低，随访第0、15、30、45天的评分分别从229.50 ± 75.91降至203.12 ± 71.71（p < 0.1018）、150.61 ± 55.32（p < 0.0001）和123.76 ± 54.81（p < 0.0001）。
本研究表明，JS在减轻IBS的总体症状方面，在严重程度及对生活质量的影响方面是安全有效的，可作为IBS的替代治疗及辅助治疗方法。
